Insight Molecular DiagnosticsIMDX
Fair Value
US$4
Share price08 Jan
US$4.5914.7% overvalued intrinsic discount
1Y61.62%
7D-18.62%
Delayed FDA Approval And Slow Transplant Adoption Will Undermine Long Term Prospects
AN
Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.
Published
08 Jan 26
Views
11
Not Invested